ENLV · Enlivex Ltd.
AI read · Good for ENLV
The AI's read
The stronger response among treated patients gives Enlivex a reason to keep developing Allocetra for knee osteoarthritis. Similar response patterns at 3 and 6 months add support. Still, this was an early-stage study, and nearly half of placebo patients also responded. The result is encouraging, but it does not yet show how well the treatment works for a wider group.